Epstein-Barr virus latent antigens EBNA3C and EBNA1 modulate epithelial to mesenchymal transition of cancer cells associated with tumor metastasis

被引:33
|
作者
Gaur, Nivedita [1 ]
Gandhi, Jaya [1 ]
Robertson, Erle S. [2 ,3 ]
Verma, Subhash C. [4 ]
Kaul, Rajeev [1 ]
机构
[1] Univ Delhi South Campus, Dept Microbiol, New Delhi 110021, India
[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Dept Microbiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Tumour Virol Program, Philadelphia, PA 19104 USA
[4] Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA
关键词
EBV; Metastasis; EMT; EBNA3C; E-CADHERIN; PROTEIN; EXPRESSION; BINDING; SUPPRESSOR; DELTA-EF1; MECHANISMS; REPRESSOR; PROMOTER; DOMAINS;
D O I
10.1007/s13277-014-2941-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial-mesenchymal transition is an important mechanism in cancer invasiveness and metastasis. We had previously reported that cancer cells expressing Epstein-Barr virus (EBV) latent viral antigens EBV nuclear antigen EBNA3C and/or EBNA1 showed higher motility and migration potential and had a propensity for increased metastases when tested in nude mice model. We now show that both EBNA3C and EBNA1 can modulate cellular pathways critical for epithelial to mesenchymal transition of cancer cells. Our data confirms that presence of EBNA3C or EBNA1 result in upregulation of transcriptional repressor Slug and Snail, upregulation of intermediate filament of mesenchymal origin vimentin, upregulation of transcription factor TCF8/ZEB1, downregulation as well as disruption of tight junction zona occludens protein ZO-1, downregulation of cell adhesion molecule E-cadherin, and nuclear translocation of beta-catenin. We further show that the primary tumors as well as metastasized lesions derived from EBV antigen-expressing cancer cells in nude mice model display EMT markers expression pattern suggesting their greater propensity to mesenchymal transition.
引用
收藏
页码:3051 / 3060
页数:10
相关论文
共 50 条
  • [41] USP7 Inhibitors Destabilize EBNA1 and Suppress Epstein-Barr Virus Tumorigenesis
    Chen, Christopher
    Addepalli, Kush
    Soldan, Samantha S.
    Castro-Munoz, Leonardo Josue
    Preston-Alp, Sarah
    Patel, Rishi J.
    Albitz, Coltin J.
    Tang, Hsin-Yao
    Tempera, Italo
    Lieberman, Paul M.
    JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (01)
  • [42] A potential NES of the Epstein-Barr virus nuclear antigen 1 (EBNA1) does not confer shuttling
    Fischer, N
    Voss, MD
    Muller-Lantzsch, N
    Grässer, FA
    FEBS LETTERS, 1999, 447 (2-3): : 311 - 314
  • [43] Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C
    Grundhoff, AT
    Kremmer, E
    Türecin, Ö
    Glieden, A
    Gindorf, C
    Atz, J
    Mueller-Lantzsch, N
    Schubach, WH
    Grässer, FA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) : 19136 - 19144
  • [44] Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21
    Radkov, SA
    Bain, M
    Farrell, PJ
    West, M
    Rowe, M
    Allday, MJ
    JOURNAL OF VIROLOGY, 1997, 71 (11) : 8552 - 8562
  • [45] Characterization of a cancer-associated Epstein-Barr virus EBNA1 variant reveals a novel interaction with PLOD1 and PLOD3
    Shire, Kathy
    Marcon, Edyta
    Greenblatt, Jack
    Frappier, Lori
    VIROLOGY, 2021, 562 : 103 - 109
  • [46] Human CD4+ T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
    Münz, C
    Bickham, KL
    Subklewe, M
    Tsang, ML
    Chahroudi, A
    Kurilla, MG
    Zhang, D
    O'Donnell, M
    Steinman, RM
    JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (10): : 1649 - 1660
  • [47] Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1
    Yin, Y
    Manoury, B
    Fåhraeus, R
    SCIENCE, 2003, 301 (5638) : 1371 - 1374
  • [48] Expression, purification, and immunogenic characterization of Epstein-Barr virus recombinant EBNA1 protein in Pichia pastoris
    Wang, Man
    Jiang, Shuai
    Liu, Xiaoying
    Wang, Yefu
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2013, 97 (14) : 6251 - 6262
  • [49] Computational analysis of EBNA1 “druggability” suggests novel insights for Epstein-Barr virus inhibitor design
    Eleonora Gianti
    Troy E. Messick
    Paul M. Lieberman
    Randy J. Zauhar
    Journal of Computer-Aided Molecular Design, 2016, 30 : 285 - 303
  • [50] EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer
    Soldan, Samantha S.
    Anderson, Emma M.
    Frase, Drew M.
    Zhang, Yue
    Caruso, Lisa B.
    Wang, Yin
    Deakyne, Julianna S.
    Gewurz, Benjamin E.
    Tempera, Italo
    Lieberman, Paul M.
    Messick, Troy E.
    GASTRIC CANCER, 2021, 24 (05) : 1076 - 1088